alzheon, Author at Alzheon | Preserving Future Memories - Page 13 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 202 blog entries.

6 Aug, 2018

Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease

alzheon2024-08-02T11:00:26-04:00August 6th, 2018|

6 Aug, 2018

Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors

alzheon2024-08-05T14:56:26-04:00August 6th, 2018|

3 Aug, 2018

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain

alzheon2024-06-19T16:49:25-04:00August 3rd, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|

23 Jul, 2018

Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801

alzheon2024-08-05T15:03:03-04:00July 23rd, 2018|

22 May, 2018

Alzheon to Make Presentations at Upcoming Industry and Investor Conferences

alzheon2024-08-05T18:11:36-04:00May 22nd, 2018|

2 Nov, 2017

Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease

alzheon2024-08-05T17:37:42-04:00November 2nd, 2017|

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

24 Oct, 2017

FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease

alzheon2024-08-05T17:32:43-04:00October 24th, 2017|

24 Oct, 2017

Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease

alzheon2024-08-05T19:12:51-04:00October 24th, 2017|